Insmed Inc. has identified cathepsin C (dipeptidyl peptidase I; DPP-1) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, bronchiectasis, asthma, cystic fibrosis, lupus nephritis, pulmonary hypertension and rheumatoid arthritis.